NCT05184569
Veri-T: A Trial of Verdiperstat in Patients With svPPA Due to TDP-43 Pathology
Active, Not Recruiting
PHASE1Ages 18–85InterventionalTreatmentPeter Ljubenkov, MDInvestigator-initiated
~64 participants
Updated 2026-07-06 on ClinicalTrials.gov
What's tested:Verdiperstat
At a glance
Recruiting sites
0 of 5 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of Treatment-Emergent Adverse Events
Measured over 24 Weeks
Conditions
Where it's being run
5 sites across 5 statesCalifornia1
Illinois1
Minnesota1
Pennsylvania1
Texas1
Study leadership
- Peter Ljubenkov, MD · PRINCIPAL_INVESTIGATOR · University of California, San Francisco
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Exclusion
c. behavioral variant for frontotemporal dementia (bvFTD; Rascovsky et al. 2011). Patients who meet diagnostic criteria for svPPA (Gorno-Tempini et al. 2011) may still be included if they have a secondary diagnosis of bvFTD, so long as the PI can reasonably attribute their disinhibition, dietary changes, compulsions, and/or loss of empathy to anterior temporal lobe atrophy (Seeley et al. 2005) and MRI is consistent with right anterior atrophy (or left temporal atrophy in participants with suspected right hemispheric language dominance);
What this trial measures
- Incidence of Treatment-Emergent Adverse Events24 Weeks
Assess adverse events during 6 months administration of Verdiperstat or Placebo